The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What are the latest updates on trispecific antibodies for the treatment of MM?
Featured:
Mohamad MohtyDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the latest updates on trispecific antibodies for the treatment of multiple myeloma?
What are the latest updates on trispecific antibodies for the treatment of MM?
Mohty begins by sharing the latest results from the phase I trial of HPN217 (NCT04184050), a B-cell maturation antigen-targeted trispecific antibody, for the treatment of relapsed/refractory multiple myeloma. He then provides background on the structure and mechanism of action of HPN217 and outlines the latest safety and efficacy data from the dose escalation phase. Finally, Mohty offers his expert perspective on the ongoing development and clinical applications of trispecific antibodies in the treatment of multiple myeloma.